Chronic stable angina positron emission tomography (PET): Difference between revisions
No edit summary |
|||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Chronic stable angina}} | {{Chronic stable angina}} | ||
'''Editor-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto: | '''Editor-In-Chief:''' [[C. Michael Gibson, M.S., M.D.]] [mailto:charlesmichaelgibson@gmail.com] Phone:617-632-7753; '''Associate Editor(s)-in-Chief:''' {{CZ}}; Smita Kohli, M.D. | ||
==Overview== | ==Overview== | ||
[[Positron emission tomography]] is of particular value in the assessment of regional coronary blood flow reserve, myocardial perfusion, and the presence and extent of [[hibernating myocardium]]. | [[Positron emission tomography]] is of particular value in the assessment of regional coronary blood flow reserve, myocardial perfusion, and the presence and extent of [[hibernating myocardium]]. | ||
==PET | ==PET== | ||
* | * Rubidium-82 or [[ammonia]] (N13) can be used for assessment of myocardial perfusion. | ||
* Labeled carbohydrates such as | * Labeled carbohydrates such as fludeoxyglucose F-18, lipids, and some amino acids can be used to asses myocardial metabolism and viable ischemic myocardium. | ||
==Indications== | ===Indications=== | ||
PET is of value principally in | PET is of value principally in difficult situations where in myocardial perfusion by [[Chronic stable angina myocardial perfusion scintigraphy|thallium scintigraphy]] and assessment of left ventricular systolic function by [[Chronic stable angina echocardiography|echocardiography]] do not reveal the extent of [[hibernating myocardium]]. | ||
==Sensitivity and Specificity== | ===Sensitivity and Specificity=== | ||
With combined assessment of myocardial perfusion and metabolism, the sensitivity and specificity for the detection of [[CAD]] may approach 95%. | With combined assessment of myocardial perfusion and metabolism, the sensitivity and specificity for the detection of [[CAD]] may approach 95%. | ||
==Disadvantages== | ===Disadvantages=== | ||
Positron emission tomography is a very expensive noninvasive test and not readily available in every cardiac diagnostic care center. | Positron emission tomography is a very expensive noninvasive test and not readily available in every cardiac diagnostic care center. | ||
''For more information on techniques used to assess myocardial viability, click [[Exercise stress testing#Techniques used to Assess Myocardial Viability|here]].'' | |||
==References== | ==References== | ||
| Line 27: | Line 26: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Disease]] | |||
[[Category:Ischemic heart diseases]] | |||
[[Category:Cardiology]] | |||
[[Category:Emergency medicine]] | |||
[[Category:Intensive care medicine]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Up-To-Date cardiology]] | |||
Latest revision as of 14:37, 5 February 2013
|
Chronic stable angina Microchapters | ||
|
Classification | ||
|---|---|---|
| ||
| ||
|
Differentiating Chronic Stable Angina from Acute Coronary Syndromes | ||
|
Diagnosis | ||
|
Alternative Therapies for Refractory Angina | ||
|
Discharge Care | ||
|
Guidelines for Asymptomatic Patients | ||
|
Case Studies | ||
|
Chronic stable angina positron emission tomography (PET) On the Web | ||
|
FDA on Chronic stable angina positron emission tomography (PET) | ||
|
CDC onChronic stable angina positron emission tomography (PET) | ||
|
Chronic stable angina positron emission tomography (PET) in the news | ||
|
Blogs on Chronic stable angina positron emission tomography (PET) | ||
|
to Hospitals Treating Chronic stable angina positron emission tomography (PET) | ||
|
Risk calculators and risk factors for Chronic stable angina positron emission tomography (PET) | ||
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753; Associate Editor(s)-in-Chief: Cafer Zorkun, M.D., Ph.D. [2]; Smita Kohli, M.D.
Overview
Positron emission tomography is of particular value in the assessment of regional coronary blood flow reserve, myocardial perfusion, and the presence and extent of hibernating myocardium.
PET
- Rubidium-82 or ammonia (N13) can be used for assessment of myocardial perfusion.
- Labeled carbohydrates such as fludeoxyglucose F-18, lipids, and some amino acids can be used to asses myocardial metabolism and viable ischemic myocardium.
Indications
PET is of value principally in difficult situations where in myocardial perfusion by thallium scintigraphy and assessment of left ventricular systolic function by echocardiography do not reveal the extent of hibernating myocardium.
Sensitivity and Specificity
With combined assessment of myocardial perfusion and metabolism, the sensitivity and specificity for the detection of CAD may approach 95%.
Disadvantages
Positron emission tomography is a very expensive noninvasive test and not readily available in every cardiac diagnostic care center.
For more information on techniques used to assess myocardial viability, click here.